Option Care Health (NASDAQ:OPCH) Sees Strong Trading Volume on Better-Than-Expected Earnings

Option Care Health, Inc. (NASDAQ:OPCH) shares saw strong trading volume on Tuesday following a better than expected earnings announcement. 1,565,199 shares were traded during trading, an increase of 27% from the previous session’s volume of 1,232,796 shares.The stock last traded at $30.46 and had previously closed at $30.41.

The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. The firm had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period in the previous year, the firm posted $0.21 EPS. The company’s revenue for the quarter was up 12.8% compared to the same quarter last year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on OPCH shares. Jefferies Financial Group boosted their target price on shares of Option Care Health from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Barrington Research reiterated an “outperform” rating and set a $38.00 target price on shares of Option Care Health in a research report on Wednesday.

Insider Transactions at Option Care Health

In other news, Director Harry M. Jansen Kraemer, Jr. bought 35,000 shares of Option Care Health stock in a transaction dated Monday, February 26th. The stock was purchased at an average price of $31.55 per share, for a total transaction of $1,104,250.00. Following the purchase, the director now directly owns 269,528 shares in the company, valued at approximately $8,503,608.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.64% of the company’s stock.

Hedge Funds Weigh In On Option Care Health

Several institutional investors have recently added to or reduced their stakes in OPCH. Park Place Capital Corp boosted its position in Option Care Health by 48.4% during the first quarter. Park Place Capital Corp now owns 1,140 shares of the company’s stock worth $38,000 after purchasing an additional 372 shares during the period. Vontobel Holding Ltd. boosted its position in Option Care Health by 2.9% during the third quarter. Vontobel Holding Ltd. now owns 13,168 shares of the company’s stock worth $426,000 after purchasing an additional 374 shares during the period. Parallel Advisors LLC boosted its position in Option Care Health by 130.2% during the fourth quarter. Parallel Advisors LLC now owns 845 shares of the company’s stock worth $28,000 after purchasing an additional 478 shares during the period. Securian Asset Management Inc. boosted its position in Option Care Health by 3.4% during the third quarter. Securian Asset Management Inc. now owns 15,235 shares of the company’s stock worth $493,000 after purchasing an additional 503 shares during the period. Finally, Sheets Smith Wealth Management boosted its position in Option Care Health by 1.6% during the third quarter. Sheets Smith Wealth Management now owns 32,542 shares of the company’s stock worth $1,053,000 after purchasing an additional 510 shares during the period. Institutional investors own 98.05% of the company’s stock.

Option Care Health Price Performance

The company has a quick ratio of 1.33, a current ratio of 1.77 and a debt-to-equity ratio of 0.74. The stock has a market cap of $5.09 billion, a P/E ratio of 19.27, a price-to-earnings-growth ratio of 1.74 and a beta of 1.22. The business’s 50-day simple moving average is $32.04 and its two-hundred day simple moving average is $31.50.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.